Griseofulvin PCD Pharma Franchise Company
Cafoli Lifecare offers 3 Griseofulvin tablet formulations for PCD pharma franchise and third-party manufacturing. Every batch is produced in WHO-GMP certified facilities, giving distributors a dependable oral antifungal for the dermatology segment.
What is Griseofulvin?
Griseofulvin is an oral antifungal antibiotic derived from Penicillium species. It binds to keratin in newly formed skin, hair and nails and disrupts fungal microtubule function, so infected tissue is gradually replaced by fungus-free tissue. See MedlinePlus for detailed drug information.
Therapeutic Applications
Griseofulvin is used to treat dermatophyte infections of the skin, hair and nails — including tinea capitis (scalp ringworm), tinea corporis, tinea cruris and onychomycosis — where topical therapy is insufficient. It is prescribed chiefly by dermatologists and general physicians.
Why Griseofulvin is a High-Potential Molecule for Distributors
Fungal skin infections are extremely common across India’s humid climate, and griseofulvin remains the classic oral choice for tinea capitis in children, where several newer antifungals are less established. Treatment courses run for weeks, generating repeat sales, and the molecule faces relatively limited PCD competition — a useful niche for dermatology-focused franchise partners.
Why Choose Cafoli Lifecare
Cafoli Lifecare supports partners with monopoly PCD rights, WHO-GMP manufacturing, DCGI-approved formulations, complete promotional inputs and a network of 1000+ franchise partners across India.
References
- MedlinePlus – Griseofulvin
- PubChem – Griseofulvin
- PubMed – Griseofulvin research
Our formulations of Griseofulvin find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: